Therefore, the increase in cardiotoxicity risk limits the applicability of findings demonstrating that a combination of trastuzumab and anthracyclines increases HER2+ breast cancer survival rates by 35% (Slamon et al., 2011; Perez et al., 2008a). The gene discussed is ERBB2; the disease is breast carcinoma.